Pfizer announced it is putting an additional $500 million into the construction of its gene therapy manufacturing site in Sanford, North Carolina. It is planned to support the company’s investment in gene therapy research and development, much...
Read moreYaoyanshe, a Shanghai on-line AI-based CRO/CMO, raised $42 million in a C funding round led by Eastern Bell Capital and Sequoia China. Founded in 2015, Yaoyanshe offers Trial.Link, a repository of China clinical trial information that connects...
Read moreAlligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached with Biotheus Inc. (“Biotheus”), a privately held Chinese company based in Zhuhai, Guangdong, China. Under the license...
Read moreAbbisko Therapeutics, a Shanghai clinical-stage biopharma, received approval to begin a US Phase I trial for ABSK021, a small molecule CSF-1R inhibitor. By inhibiting CSF-1R, ABSK021 is expected to reprogram tumor-associated macrophages (TAMs)...
Read moreSuzhou Kintor Pharmaceuticals signed a cooperation agreement with CMAB Biopharma (Suzhou), a biologics CDMO, to develop and manufacture Kintor’s ALK-1 mAb. Kintor in-licensed global rights to the candidate from Pfizer, which previously...
Read moreClick here to find more details This is NAI’s new China News Weekly. We will be covering the latest Chinese foreign investment trends every week. To continue to receive our China News Weekly, please click the button below to subscribe.
Read moreLHHC Medical Technology, a China AI company, announced a global cooperation with Vancouver’s Enlighta to market LHHC’s early cancer detection test. The “No Cancer” technology combines LHHC’s AI data models and...
Read moreShenzhen Xpect Vision Technology closed a $14 million B financing to support development of its new imaging technologies. Founded in 2015, Xpect considers itself a leader in photon-counting X-ray imaging along with other new technologies such as...
Read moreShenzhen’s China Medical System acquired China rights to seven generic drugs from India’s Sun Pharma. The seven drugs were not identified, but Sun Pharma said they have China market revenues of $1 billion annually. Two months ago, CMS...
Read moreIndia’s Natco Pharma, a company that specializes in complex generics, plans to build up its business in China, taking advantage of China’s speeded-up approval process to register products that are already approved elsewhere. Natco has...
Read moreNanjing Frontier Biotechnologies was approved to stage a $285 million IPO on the Shanghai STAR Exchange. Frontier has a China approved treatment for HIV, and it is developing another HIV treatment that it in-licensed from the Rockefeller...
Read moreBeijing Baicare Biotech closed a $9 million B financing that was led by Sinopharm Capital and included the company’s existing shareholders. Formed in 2013, Baicare makes automated nucleic acid detection devices for clinical use using...
Read more
